Hyloris Pharmaceuticals S.A.
HYL.BR · BRU
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €10,042 | €2,087 | €2,951 | €3,096 |
| % Growth | 381.2% | -29.3% | -4.7% | – |
| Cost of Goods Sold | €227 | €93 | €94 | €107 |
| Gross Profit | €9,815 | €1,994 | €2,857 | €2,989 |
| % Margin | 97.7% | 95.5% | 96.8% | 96.5% |
| R&D Expenses | €10,265 | €14,421 | €10,151 | €5,056 |
| G&A Expenses | €5,627 | €5,546 | €3,517 | €2,900 |
| SG&A Expenses | €5,627 | €5,546 | €3,517 | €2,900 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | €1,053 | -€1,980 | -€303 | €5,381 |
| Operating Expenses | €16,945 | €17,987 | €13,365 | €13,337 |
| Operating Income | -€7,130 | -€15,993 | -€11,638 | -€4,944 |
| % Margin | -71% | -766.3% | -394.4% | -159.7% |
| Other Income/Exp. Net | €788 | €613 | -€263 | -€741 |
| Pre-Tax Income | -€6,342 | -€15,380 | -€11,901 | -€11,282 |
| Tax Expense | -€81 | -€593 | €4 | €297 |
| Net Income | -€6,342 | -€15,380 | -€11,906 | -€11,579 |
| % Margin | -63.2% | -736.9% | -403.5% | -374% |
| EPS | -0.22 | -0.55 | -0.44 | -0.45 |
| % Growth | 60% | -25% | 2.2% | – |
| EPS Diluted | -0.22 | -0.55 | -0.44 | -0.45 |
| Weighted Avg Shares Out | 29,042 | 28,000 | 27,199 | 25,833 |
| Weighted Avg Shares Out Dil | 29,042 | 28,000 | 27,199 | 25,833 |
| Supplemental Information | – | – | – | – |
| Interest Income | €901 | €869 | €67 | €32 |
| Interest Expense | €135 | €100 | €285 | €583 |
| Depreciation & Amortization | €1,229 | €348 | €196 | €114 |
| EBITDA | -€4,848 | -€14,980 | -€11,433 | -€10,781 |
| % Margin | -48.3% | -717.8% | -387.4% | -348.2% |